Wheeze Detection in Adults During Dynamic Bronchial Situations Measured by PulmoTrack® 2010 With WIM-PC™ Technologies Recording

KarmelSonix

Status

Unknown

Conditions

Asthma, Bronchial

Treatments

Device: PulmoTrack® 2010 with WIM-PC™ Technologies

Study type

Observational

Funder types

Industry

Identifiers

NCT00644462

KSI-WZA-01

Details and patient eligibility

About

The PulmoTrack® 2010 with WIM-PC™ Technologies device, indicated for acoustic pulmonary function measurement that quantifies the presence of wheezing. This study was designed in order to evaluate the efficacy and safety of using the WIM-PC™ device for wheeze detection during dynamic bronchial situations in asthmatic adult.

Full description

Asthma is defined by the National Asthma Education and Prevention Program (NAEPP) guideline as a 'Chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The asthma guideline states that inflammation causes recurrent episodes of wheezing, breathlessness and chest tightness that are associated with widespread but variable airflow obstruction.

Wheeze quantification by lung sounds analysis methods is objective, non invasive and has been shown to correlate with clinical status in asthma and bronchiolitis. The recording procedure is simple, requiring only the attachment of 4 ECG-size sensors to the chest wall. A 30-second recording is often adequate to obtain good quality data, where wheezes are detected and counted with high degree of accuracy.

Karmel Sonix Ltd has developed the PulmoTrack® 2010 with WIM-PC™ Technologies device, indicated for acoustic pulmonary function measurement that quantifies the presence of wheezing. This study was designed in order to evaluate the efficacy and safety of using the PulmoTrack® 2010 with WIM-PC™ Technologies device for wheeze detection during dynamic bronchial situations in asthmatic adults.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Asthmatic or healthy subjects;
Age 18 and up;
Not smoking for at the last two years;
Subject or subject's parents/guardian is able to comprehend and give informed consent for participation in the study.

Exclusion criteria

Chest burns;
COPD;
Pregnant or lactating;
Mechanically ventilatory;
Homodynamic instability;
Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to screening;
Acute infection requiring intravenous antibiotics at the time of screening;
Uncontrolled bleeding and coagulation disorders;
Uncontrolled diabetes mellitus: IDDM or NIDDM;
HIV positive or any other immunosuppressive disorder;
Subject objects to the study protocol;
Concurrent participation in any other clinical study;
Physician objection.